iwMyeloma 2022 | Precursor conditions: the importance of screening and early intervention in myeloma
In this video, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of precursor conditions and curing myeloma with early intervention. Dr Ghobrial first highlights three important pillars for the treatment of myeloma: screening and early detection, risk stratification, and precision interception, and further explains the importance of these. Dr Ghobrial then discusses the importance of screening patients for precursor conditions including smoldering myeloma, monoclonal gammopathy of undetermined significance (MGUS) and monoclonal gammopathy of indeterminate potential (MGIP), and briefly discusses the iStopMM study (NCT03327597). Following this, Dr Ghobrial highlights risk stratification models, including the 20/2/20 model, and the importance of using these models at an early stage in diagnosis. To conclude, Dr Ghobrial discusses disease interception and cytogenetics, measurable residual disease (MRD), and the importance of using novel agents such as chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies at an earlier stage. This interview took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
